Omalizumab

[MAF] Omalizumab (Xolair) Injection 150 mg

1. Additional clinical criteria applies
   
   As an add-on therapy to H₁-antihistamines for treating severe chronic spontaneous urticaria (CSU) in patients aged 12 years and older, with a mean weekly Urticaria Activity Score (UAS

2. of 28 and above, despite the use of, or who are intolerant to, four-times registered dose of second generation non-sedating H₁-antihistamines.
   
   A maximum of six 300 mg doses of omalizumab should be administered for each treatment course. Re-treatment with omalizumab can be considered upon relapse for patients who achieve an adequate response during the previous treatment course. Adequate response to omalizumab is defined as a UAS7 score of six or below while on treatment.

[MAF] Omalizumab (Xolair) Prefilled Syringe 150 mg/mL

1. Additional clinical criteria applies
   
   As an add-on therapy to H₁-antihistamines for treating severe chronic spontaneous urticaria (CSU) in patients aged 12 years and older, with a mean weekly Urticaria Activity Score (UAS

2. of 28 and above, despite the use of, or who are intolerant to, four-times registered dose of second generation non-sedating H₁-antihistamines.
   
   A maximum of six 300 mg doses of omalizumab should be administered for each treatment course. Re-treatment with omalizumab can be considered upon relapse for patients who achieve an adequate response during the previous treatment course. Adequate response to omalizumab is defined as a UAS7 score of six or below while on treatment.

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

01/09/2020 Benralizumab, mepolizumab and omalizumab for treating severe asthma

[NR] The Ministry of Health’s Drug Advisory Committee has not recommended listing:

• Benralizumab and mepolizumab on the Medication Assistance Fund (MAF) for treating severe eosinophilic asthma; and

• Omalizumab on the MAF for treating severe allergic asthma

due to unacceptable cost-effectiveness at the prices proposed by the manufacturers.

02/01/2019 Omalizumab for treating antihistamine-resistant chronic spontaneous urticaria

The Ministry of Health’s Drug Advisory Committee has recommended:

• Omalizumab 150 mg powder and solvent for solution for injection as an add-on therapy to H₁-antihistamines for treating severe chronic spontaneous urticaria (CSU) in patients aged 12 years and older, with a mean weekly Urticaria Activity Score (UAS7) of 28 and above, despite the use of, or who are intolerant to, four-times registered dose of second-generation non-sedating H₁-antihistamines.

A maximum of six 300 mg doses of omalizumab should be administered for each treatment course. Re-treatment with omalizumab can be considered upon relapse for patients who achieve an adequate response during the previous treatment course.

Adequate response to omalizumab is defined as a UAS7 score of six or below while on treatment.

Omalizumab should be prescribed by a specialist physician (immunologist, allergist, or dermatologist) with experience in managing CSU.

Subsidy status

[R] Omalizumab 150 mg powder and solvent for solution for injection is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.

[R] Omalizumab should be used in line with the clinical criteria in the MAF checklist for initial and continuing prescriptions.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration